You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Medtronic
Baxter
Colorcon
Merck

Last Updated: May 30, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OLANZAPINE

» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Olanzapine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000373 Treatment of Obsessive-Compulsive Disorder Completed National Institute of Mental Health (NIMH) Phase 4 1992-09-01 The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
NCT00000373 Treatment of Obsessive-Compulsive Disorder Completed University of Florida Phase 4 1992-09-01 The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
NCT00000374 Treatment for First-Episode Schizophrenia Completed National Institute of Mental Health (NIMH) Phase 4 1998-09-01 This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
NCT00000374 Treatment for First-Episode Schizophrenia Completed The Zucker Hillside Hospital Phase 4 1998-09-01 This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
NCT00000374 Treatment for First-Episode Schizophrenia Completed Northwell Health Phase 4 1998-09-01 This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Olanzapine

Condition Name

Condition Name for Olanzapine
Intervention Trials
Schizophrenia 207
Bipolar Disorder 53
Schizoaffective Disorder 52
Psychotic Disorders 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Olanzapine
Intervention Trials
Schizophrenia 220
Psychotic Disorders 84
Disease 77
Bipolar Disorder 65
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Olanzapine

Trials by Country

Trials by Country for Olanzapine
Location Trials
United States 880
Canada 65
Spain 36
Germany 33
China 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Olanzapine
Location Trials
New York 72
California 62
Texas 48
Ohio 47
Florida 42
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Olanzapine

Clinical Trial Phase

Clinical Trial Phase for Olanzapine
Clinical Trial Phase Trials
Phase 4 148
Phase 3 105
Phase 2/Phase 3 11
[disabled in preview] 65
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Olanzapine
Clinical Trial Phase Trials
Completed 284
Recruiting 45
Terminated 31
[disabled in preview] 42
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Olanzapine

Sponsor Name

Sponsor Name for Olanzapine
Sponsor Trials
Eli Lilly and Company 82
National Institute of Mental Health (NIMH) 30
Pfizer 16
[disabled in preview] 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Olanzapine
Sponsor Trials
Other 384
Industry 239
NIH 45
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
AstraZeneca
Dow
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.